LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna today announced that the Company will release its first quarter 2020 financial results after market close on Thursday, May 7, 2020.
Author: Business Wire
Ocular Therapeutix™ To Report First Quarter 2020 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fi…
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
ELT Sight’s ExTra Excimer Laser Trabeculostomy Procedure Receives New CPT® Codes from American Medical Association
LOS ANGELES & MUNICH–(BUSINESS WIRE)–AMA approves 2 Category III CPT codes for ELT Sight’s ExTra Excimer Laser Trabeculostomy Procedure
Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its fi…
Mojo Vision Raises Additional $51 Million+ in Series B-1 Round, Funding Development of First True Smart Contact Lens
SARATOGA, Calif.–(BUSINESS WIRE)–Mojo Vision, the Invisible Computing company, today announced it has raised more than $51 million in a Series B-1 investment round to propel the development of the first true smart contact lens, Mojo Lens. This new ro…
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Global Ophthalmology PACS Market 2020-2024 | Evolving Opportunities with Agfa-Gevaert NV and Carestream Health Inc. | Technavio
LONDON–(BUSINESS WIRE)– #GlobalOphthalmologyPACSMarket–The global ophthalmology PACS market size has the potential to grow by USD 59.9 million during 2020-2024.
Insights on the Worldwide Ophthalmology Therapeutics Industry to 2024 – Key Drivers and Challenges – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmology Therapeutics Market 2020-2024” report has been added to ResearchAndMarkets.com’s offering. The author has been monitoring the global ophthalmology therapeutics market and it is poised to grow by USD 10…
Second Sight Medical Products Provides Business Update
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision…
IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its first quarter 2020 financial and operating results on Wednesday, May 6, 2020.
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Lugano : la nouvelle frontière de l'ophtalmologie
LUGANO, Suisse–(BUSINESS WIRE)–Baptisée “Protocole de Lugano”, cette combinaison de photons et de nutraceutiques s’est révélée efficace dans le traitement de la DMLA (dégénérescence maculaire liée à l’âge), principale cause de cécité dans le monde. L…
Aus Lugano: die neue Errungenschaft in der Augenheilkunde
LUGANO, Schweiz–(BUSINESS WIRE)–Sie ist unter dem Namen Lugano-Protokoll bekannt und beschreibt eine Kombination aus Photonen und Nahrungsergänzungsmittel, die sich in der Behandlung der AMD (altersbedingte Makuladegeneration), der Hauptursache für E…
Uit Lugano: de nieuwe grens in de oogheelkunde
LUGANO, Zwitserland–(BUSINESS WIRE)–Het staat bekend als het Lugano-protocol en is de naam die wordt gegeven aan een combinatie van fotonen en nutraceuticals waarvan is aangetoond dat deze effectief is bij de behandeling van LMD (leeftijdsgebonden ma…
Desde Lugano: La nueva frontera de la oftalmología
LUGANO, Suiza–(BUSINESS WIRE)–Se conoce como el Protocolo de Lugano, y es el nombre que recibe una combinación de fotones y nutracéuticos que ha demostrado ser eficaz en el tratamiento de la DMAE (degeneración macular asociada a la edad), la principa…
DA LUGANO LA NUOVA FRONTIERA IN OCULISTICA
LUGANO, Svizzera–(BUSINESS WIRE)–Si chiama Lugano Protocol il progetto messo a punto dal Dr. Roberto Pinelli dello Switzerland Eye Research Institute efficace nel trattamento della maculopatia, la patologia oculare principale causa di cecità nel mond…
From Lugano: The New Frontier in Ophthalmology
LUGANO, Switzerland–(BUSINESS WIRE)–From Lugano: The New Frontier in Ophthalmology.
AvellinoCoV2 Genetic Test Included in OC Health Care Agency OC COVID-19 Testing Network Launch
MENLO PARK, Calif.–(BUSINESS WIRE)– #avellinocoronatest–Avellino and OC HCA launched network in OC, Calif. to provide COVID-19 tests for residents unable to access tests through their medical providers.